NASA’s Artemis II mission to on board Opella’s Dulcolax for lunar orbit mission

A brand from Opella will be part of the official NASA astronaut formulary

AptarGroup nasal spray tech joins ENA respiratory’s Phase II trial of INNA?051

The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention

Glenmark Therapeutics USA launches fluticasone propionate nasal spray

The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million

Esperion to acquire Corstasis, gaining first FDA-approved nasal spray Diuretic

FDA approves Tezspire for chronic rhinosinusitis with nasal polyps

Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation

AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps

Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent

FDA approves Corstasis’ bumetanide nasal spray to treat edema in heart, liver, and kidney disease

Strides partners with Kenox to expand nasal spray portfolio for US market

Kenox to provide formulation and development expertise in orally inhaled and nasal drug products

Milestone Pharmaceuticals announces FDA acceptance of response to Cardamyst nasal spray CRL

Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments

Lupin launches nasal spray in US

Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals